Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112


Lymphoid hyperplasia and lymphoma in transgenic mice expressing the small non-coding RNA, EBER1 of Epstein-Barr virus.

Repellin CE, Tsimbouri PM, Philbey AW, Wilson JB.

PLoS One. 2010 Feb 8;5(2):e9092. doi: 10.1371/journal.pone.0009092.


The in vivo binding site for oncoprotein c-Myc in the promoter for Epstein-Barr virus (EBV) encoding RNA (EBER) 1 suggests a specific role for EBV in lymphomagenesis.

Niller HH, Salamon D, Ilg K, Koroknai A, Banati F, Bauml G, Rucker O, Schwarzmann F, Wolf H, Minarovits J.

Med Sci Monit. 2003 Jan;9(1):HY1-9.


Proteomics and Transcriptomics of BJAB Cells Expressing the Epstein-Barr Virus Noncoding RNAs EBER1 and EBER2.

Pimienta G, Fok V, Haslip M, Nagy M, Takyar S, Steitz JA.

PLoS One. 2015 Jun 29;10(6):e0124638. doi: 10.1371/journal.pone.0124638. eCollection 2015.


Epstein-Barr virus-encoded EBNA1 enhances RNA polymerase III-dependent EBER expression through induction of EBER-associated cellular transcription factors.

Owen TJ, O'Neil JD, Dawson CW, Hu C, Chen X, Yao Y, Wood VH, Mitchell LE, White RJ, Young LS, Arrand JR.

Mol Cancer. 2010 Sep 15;9:241. doi: 10.1186/1476-4598-9-241.


A transgenic mouse model demonstrating the oncogenic role of mutations in the polycomb-group gene EZH2 in lymphomagenesis.

Berg T, Thoene S, Yap D, Wee T, Schoeler N, Rosten P, Lim E, Bilenky M, Mungall AJ, Oellerich T, Lee S, Lai CK, Umlandt P, Salmi A, Chang H, Yue L, Lai D, Cheng SW, Morin RD, Hirst M, Serve H, Marra MA, Morin GB, Gascoyne RD, Aparicio SA, Humphries RK.

Blood. 2014 Jun 19;123(25):3914-24. doi: 10.1182/blood-2012-12-473439. Epub 2014 May 6.


Epstein-Barr virus nuclear antigen-1 and Myc cooperate in lymphomagenesis.

Drotar ME, Silva S, Barone E, Campbell D, Tsimbouri P, Jurvansu J, Bhatia P, Klein G, Wilson JB.

Int J Cancer. 2003 Sep 1;106(3):388-95.


Rapamycin reverses splenomegaly and inhibits tumor development in a transgenic model of Epstein-Barr virus-related Burkitt's lymphoma.

Cen O, Longnecker R.

Mol Cancer Ther. 2011 Apr;10(4):679-86. doi: 10.1158/1535-7163.MCT-10-0833. Epub 2011 Jan 31.


Heterogeneous expression of Epstein-Barr virus latent proteins in endemic Burkitt's lymphoma.

Niedobitek G, Agathanggelou A, Rowe M, Jones EL, Jones DB, Turyaguma P, Oryema J, Wright DH, Young LS.

Blood. 1995 Jul 15;86(2):659-65.


Plasmacytic hyperplasia in age-related Epstein-Barr virus-associated lymphoproliferative disorders: a report of two cases.

Kojima M, Morita Y, Nakamura N, Shimizu K, Murayama K, Nakamura S.

Pathol Res Pract. 2008;204(4):267-72. doi: 10.1016/j.prp.2007.11.007. Epub 2008 Jan 9.


Atypical Epstein-Barr viral genomic structure in lymphoma tissue and lymphoid cell lines.

Tang W, Fan H, Schroeder J, Dunphy CH, Bryant RJ, Fedoriw Y, Gulley ML.

Diagn Mol Pathol. 2013 Jun;22(2):91-101. doi: 10.1097/PDM.0b013e318273fb43.


Epstein-Barr virus latent membrane protein 2A enhances MYC-driven cell cycle progression in a mouse model of B lymphoma.

Fish K, Chen J, Longnecker R.

Blood. 2014 Jan 23;123(4):530-40. doi: 10.1182/blood-2013-07-517649. Epub 2013 Oct 30.


Antagonistic effects of c-myc and Epstein-Barr virus latent genes on the phenotype of human B cells.

Pajic A, Staege MS, Dudziak D, Schuhmacher M, Spitkovsky D, Eissner G, Brielmeier M, Polack A, Bornkamm GW.

Int J Cancer. 2001 Sep;93(6):810-6.


Epstein-Barr virus (EBV) genomes and c-myc oncogene in oral Burkitt's lymphomas.

Syrjänen S, Kallio P, Sainio P, Fuju C, Syrjänen K.

Scand J Dent Res. 1992 Jun;100(3):176-80.


Increased number of Epstein-Barr virus latently infected B-cells in T-cell non-Hodgkin's lymphoma tissues.

Hojo I, Takanashi M, Hirai K, Mori S.

Arch Virol. 1995;140(8):1419-26.


IgH enhancer deregulated expression of L-myc: abnormal T lymphocyte development and T cell lymphomagenesis.

Möröy T, Fisher P, Guidos C, Ma A, Zimmerman K, Tesfaye A, DePinho R, Weissman I, Alt FW.

EMBO J. 1990 Nov;9(11):3659-66.

Supplemental Content

Support Center